



Public Pharmacy Benefit Manager Transparency Report

2024 Data

7/28/2025

REPORT PREPARED BY:

Minnesota Department of Commerce
Insurance Division

85 7th Place East St. Paul, MN 55101

651-539-1500

<https://mn.gov/commerce/insurance/>

Upon request, this material will be made available in an alternative format such as large print, Braille, or audio recording. Printed on recycled paper.

Table of Contents

Pharmacy Benefit Manager (PBM) Transparency Reporting	4
Reporting Process.....	4
Data Limitations.....	4
Definitions of Key Terms	4
PBM Transparency Public Reference Materials	6
Transparency Reporting FAQ.....	6
Claims Level Detail Template	6
Aggregate Report Template	6
Public Report Template	6
PBM Public Transparency Report Submissions	7

Pharmacy Benefit Manager (PBM) Transparency Reporting

Minn. Stat. § 62W.06 Subd. 2 requires all licensed PBMs to submit a transparency report, containing both aggregate and claims level data for the prior calendar year, to the Department of Commerce. Commerce is required to publish the public data contained in the PBM transparency reporting on its website.

Reporting Process

Instructions and three templates for reporting aggregate, claims level detail, and public data were made available on the Commerce website to all licensed PBMs.

PBMs were required to submit transparency reporting data to Commerce by June 2, 2025. Due to the varying nature of PBM business models and contracts, a given PBM may not be responsible for submitting a full report. PBMs claiming to be exempt from all reporting requirements were given the option to submit “zero” reports along with written rationale for the basis of their claim. A summary of the responses received by Commerce is shown in the table at the right.

As required by law, the public reports do not contain any information, such as claims level detail, that could lead to identification of a plan sponsor. To further protect plan sponsor identities, the public reports do not include the name of the submitting PBM.

Summary of responses from PBMs	
Total licensed PBMs	52
PBMs submitting Public Reports	30 ¹
PBMs submitting Zero Reports	19
PBMs not responding or missing reports	3

Data Limitations

- PBMs were given instructions regarding units, rounding, and calculated fields, but Commerce cannot guarantee full compliance with the reporting instructions.
- The data in this report has not been independently audited.
- While Commerce provided a data dictionary, PBM reporting may vary based on a PBM’s internal definitions of a given term.
- The public reports in this document are as submitted by the PBMs. Commerce has not vetted or modified the data, unless explicitly noted.

Definitions of Key Terms

WAC

The aggregate wholesale acquisition cost (WAC) of a given drug from the drug’s manufacturer (does not include discounts or rebates).

¹ Sum may not match total number of licensed PBMs if one or more PBMs submit multiple reports for different markets.

Net WAC

WAC minus any rebates and other fees paid to the PBM with associated claims.

Non-Plan Sponsor

Refers to network pharmacies or pharmacies in which the PBM has a contractual relationship. For the purposes of the transparency report, data from non-plan sponsors excludes any fees assessed directly to plan sponsors (such as a per member per month fee or any other quantifiable monetary restriction applicable only to the plan sponsor).

Rebates

Defined in Minn. Stat. § 62W.02 Subd. 17 as all price concessions paid by a drug manufacturer to a pharmacy benefit manager or plan sponsor, including discounts and other price concessions that are based on the actual or estimated utilization of a prescription drug. Rebates also include price concessions based on the effectiveness of a prescription drug as in a value-based or performance-based contract.

Other fees and payments

The aggregate of all fees, attributable to claims in the given category, from all sources, indirect or direct, that the PBM receives for all PBM plan sponsor clients, except those defined as rebates above. Examples of fees include transaction fees, administrative fees, fees assessed to pharmacies, and claims payments from plan sponsors.

Total Rebates and Other Fees and Payments

Calculated as a sum of *total rebates* and *other fees and payments*.

Total Rebates and Other Fees and Payments – Non Plan Sponsor

Total amount of rebates and other fees and payments except those that come directly from plan sponsors.

Retained Rebates and Other Fees and Payments – Non Plan Sponsor

The total amount of rebates and other fees and payments, except those directly from plan sponsors, that are retained by the pharmacy benefit manager as revenue for services provided.

Retained Rebates and Other Fees and Payments Percentage – Non Plan Sponsor

The amount of rebates and other fees and payments, except those directly from plan sponsors, that are retained by the pharmacy benefit manager as revenue for services provided stated as a percentage of the total collected.

Therapeutic Category

The grouping of drugs based on similar characteristics such as chemical structure, mechanism of action, or disease treated. PBMs were instructed use the US Pharmacopeia (USP) classification system and report drug groupings at the category level.

Plan Sponsor

A group purchaser as defined under Minn. Stat. § 62J.03; an employer in the case of an employee health benefit plan established or maintained by a single employer; or an employee organization in the case of a health plan established or maintained by an employee organization, an association, joint board trustees, a committee, or other similar group that establishes or maintains the health plan. This term includes a person or entity acting for

a pharmacy benefit manager in a contractual or employment relationship in the performance of pharmacy benefit management. Plan sponsor does not include the Minnesota Department of Human Services.

PBM Transparency Public Reference Materials

Supplementary materials related to the PBM Transparency Reporting can be found on the Department of Commerce's PBM webpage: <https://mn.gov/commerce/insurance/industry/pbm/>

These include the FAQ document for the 2024 reporting cycle and the three submission templates: claims level detail report, aggregate report, and public report.

Transparency Reporting FAQ

The transparency reporting FAQ was developed based on anticipated questions from PBMs on the reporting process, requirements, and parameters. The initial FAQ was submitted to all licensed PBMs on August 31, 2020, and then updated on September 21, 2020 based on feedback and questions received from PBMs. For the 2023 data cycle, Commerce added an additional field to the FAQ to clarify that the Other Fees and Payments field in the aggregate reporting template includes claims amounts charged to plan sponsors.

Claims Level Detail Template

This document was developed in August 2020 and finalized in September 2020 after incorporating feedback from licensed PBMs and other stakeholders. The template requires PBMs to populate data at the individual claims level for enrollees of plan sponsors doing business in Minnesota. The data fields are based on the list of data required under Minn. Stat. § 62W.06 Subd. 2(7)(a)(i)-(x). No subsequent substantive changes have been made to the template.

Aggregate Report Template

This document was developed in August 2020 and finalized in September 2020 after incorporating feedback from licensed PBMs and other stakeholders. The template requires PBMs to populate data at the Therapeutic Category level and summarize a number of items regarding prescription drug prices, related rebates by therapeutic category, and overall wholesale acquisition costs for all plan sponsors doing business in Minnesota. The data fields are based on the list of data required under Minn. Stat. § 62W.06 Subd. 2 (a)(1)-(6). For the 2023 data cycle, Commerce added an additional field to the Definitions tab to clarify that the Other Fees and Payments field includes claims amounts charged to plan sponsors.

Public Report Template

This document was developed in September 2020 and finalized after receiving no feedback. The template contains data fields required under Minn. Stat. § 62W.06 Subd. 2 (b), forming public reports for each PBM. Beginning with 2021 data reporting, Commerce required PBMs to complete this template in addition to the Claims Level Detail and Aggregate Report Templates. No subsequent substantive changes have been made to the template.

PBM Public Transparency Report Submissions

The remainder of this report includes the public report submissions from PBMs.

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	33%	0%	15%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 29,735,000	\$ 8,012,000	\$ 4,000	\$ 8,016,000	\$ 8,016,000	\$ 1,202,000	15%	\$ 21,719,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 5,615,000	\$ 2,416,000
Blood Glucose Regulators	\$ 5,615,000	\$ 4,107,000
Cardiovascular Agents	\$ 2,933,000	\$ 2,247,000
Respiratory Tract/Pulmonary Agents	\$ 2,637,000	\$ 2,160,000
Blood Products and Modifiers	\$ 2,297,000	\$ 1,789,000
Antineoplastics	\$ 1,968,000	\$ 1,652,000
Central Nervous System Agents	\$ 1,031,000	\$ 873,000
Dermatological Agents	\$ 881,000	\$ 725,000
Antivirals	\$ 744,000	\$ 712,000
Anti-obesity Agents	\$ 575,000	\$ 454,000

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	71%	71%	71%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 136,998	\$ 1,225	\$ 53,875	\$ 55,100	\$ 1,225	\$ 865	71%	\$ 76,649

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Central Nervous System Agents	\$ 38,972	\$ 33,069
Analgesics	\$ 18,278	\$ 6,893
Antidepressants	\$ 12,070	\$ 9,938
Antivirals	\$ 11,127	\$ 3,761
Antipsychotics	\$ 9,625	\$ 9,390
Antispasticity Agents	\$ 9,624	\$ 8,072
Antiemetics	\$ 8,360	\$ 7,005
Dermatological Agents	\$ 8,212	\$ 3,155
Blood Products and Modifiers	\$ 5,441	(221)
Skeletal Muscle Relaxants	\$ 4,369	\$ 1,710

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	47%	39%	43%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 32,333,154	\$ 4,417,124	\$ -	\$ 4,417,124	\$ 4,417,124	\$ 1,899,363	47%	\$ 27,916,030

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Tumor Necrosis Factor (TNF) Blockers	\$ 4,553,559	\$ 3,758,436
Interleukin Blockers	\$ 3,936,978	\$ 3,307,032
No USP PG, Treatment-Resistant	\$ 1,989,251	\$ 1,799,536
No USP PG, No USP Class, Anti-Obesity Agents	\$ 1,072,014	\$ 848,077
No USP PG, Electrolyte/Mineral Replacements	\$ 643,890	\$ 497,106
JAK Inhibitors	\$ 620,635	\$ 493,319
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors	\$ 653,733	\$ 479,901
Glucose Control Agents, Other	\$ 618,990	\$ 388,634
No USP PG, Dopamine Agonists	\$ 488,348	\$ 368,097
Insulin, Long-acting	\$ 250,638	\$ 107,064

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	100%	0%	1%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 897,523,821	\$ 301,074,962	\$ 800,210,522	\$ 1,101,285,484	\$ 276,387,719	\$ 4,542,420	2%	\$ (203,761,663)

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 184,124,036	\$ (50,463,775)
Blood Glucose Regulators	\$ 153,923,518	\$ (77,116,488)
Anti-obesity Agents	\$ 84,807,221	\$ (30,531,415)
Dermatological Agents	\$ 72,749,973	\$ (21,484,293)
Respiratory Tract/ Pulmonary Agents	\$ 56,010,532	\$ 107,010
Antineoplastics	\$ 54,496,917	\$ (3,795,437)
Central Nervous System Agents	\$ 37,370,684	\$ (10,493,087)
Antivirals	\$ 32,031,133	\$ (1,569,635)
Blood Products and Modifiers	\$ 24,836,134	\$ (6,221,053)
Antimigraine Agents	\$ 22,826,807	\$ (6,642,632)

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 10,681,644	\$ 694,951	\$ 3,673,242	\$ 3,943,031	\$ 3,943,031	\$ -	0%	\$ 783,374

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Disease-modifying Antirheumatic Drugs	\$ 2,648,186	\$ 250,985
Antidepressants	\$ 932,587	\$ 2,761
HMG-CoA Reductase Inhibitors	\$ 752,811	
Incretin Mimetics	\$ 622,024	\$ 138,966
Antipsychotics	\$ 305,633	\$ 5,497
Proton-pump Inhibitors	\$ 286,892	
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors	\$ 235,408	\$ 39,006
Skin and Mucous Membrane Agents, Misc	\$ 223,628	\$ 13,670
Amphetamines	\$ 211,637	\$ 577
Antiretrovirals	\$ 211,350	\$ 40,284

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 54,076,880	\$ 2,409,003	\$ -	\$ 2,409,003	\$ -	\$ -	0%	\$ -

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Cardiovascular Agents	\$ 8,773,054	\$ -
Blood Glucose Regulators	\$ 7,135,074	\$ -
Antidepressants	\$ 6,081,218	\$ -
Gastrointestinal Agents	\$ 3,111,390	\$ -
Immunological Agents	\$ 2,904,264	\$ -
Respiratory Tract/Pulmonary Agents	\$ 2,810,993	\$ -
Central Nervous System Agents	\$ 2,424,671	\$ -
Anticonvulsants	\$ 2,398,620	\$ -
Antivirals	\$ 1,819,465	\$ -
Genitourinary Agents	\$ 1,715,875	\$ -

a) all entries for WAC have been formulated using Average Wholesale Price (AWP)

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	49%	-27200%	-714%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 3,905,911,000	\$ 1,123,153,000	\$ 3,370,439,000	\$ 4,493,623,000	\$ 1,129,036,000	\$ 53,444,000	5%	\$ (587,734,000)

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
MISCELLANEOUS	\$ 651,577,000	\$ (78,521,000)
DIABETIC THERAPY	\$ 590,791,000	\$ (237,198,000)
ANTIARTHRITICS	\$ 504,622,000	\$ (151,369,000)
ALL OTHER ANTI Obesity PREPS	\$ 372,020,000	\$ (59,900,000)
ANTINEOPLASTICS	\$ 284,913,000	\$ (5,863,000)
ALL OTHER DERMATOLOGICALS	\$ 233,152,000	\$ (37,845,000)
ANTIVIRALS	\$ 165,152,000	\$ 2,175,000
BIOLOGICALS	\$ 104,610,000	\$ (18,377,000)
NON-OPIOID ANALGESICS	\$ 93,160,000	\$ (20,490,000)
ANTICOAGULANTS	\$ 91,069,000	\$ (13,502,000)

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	26%	0%	1%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 172,659,846	\$ 33,895,066	\$ 2,459,953	\$ 36,355,019	\$ 33,895,066	\$ 5,910,966	5%	\$ 136,304,827

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	\$ 22,488,850	\$ 12,966,950
ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEP.AGONIST)	\$ 11,474,722	\$ 7,799,123
ANTI-OBESITY GLUCAGON-LIKE PEPTIDE-1 RECEP AGONIST	\$ 11,077,680	\$ 8,893,575
ANTIPSORIATIC AGENTS,SYSTEMIC	\$ 10,864,337	\$ 8,789,350
MONOCLONAL ANTIBODY-HUMAN INTERLEUKIN 12/23 INHIB	\$ 10,625,708	\$ 7,125,143
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	\$ 7,036,127	\$ 6,958,992
ANTI-OBESITY - INCRETIN MIMETICS COMBINATION	\$ 6,229,246	\$ 6,001,840
INTERLEUKIN-4(IL-4) RECEPTOR ALPHA ANTAGONIST, MAB	\$ 6,187,711	\$ 5,422,636
ANTIHYPERGLYCEMIC - INCRETIN MIMETICS COMBINATION	\$ 5,086,796	\$ 3,265,813
ANTIMIGRAINE PREPARATIONS	\$ 4,383,165	\$ 3,407,023

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 569,600	\$ -	\$ -	\$ -	\$ -	\$ -	0%	\$ 569,600

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Analgesics	\$ 350,500	\$ 350,500
Anticonvulsants	\$ 54,800	\$ 54,800
Antidepressants	\$ 30,900	\$ 30,900
Gastrointestinal Agents	\$ 30,000	\$ 30,000
Ophthalmic Agents	\$ 24,200	\$ 24,200
Dermatological Agents	\$ 20,000	\$ 20,000
Anesthetics	\$ 15,800	\$ 15,800
Antivirals	\$ 4,900	\$ 4,900
Antispasticity Agents	\$ 4,800	\$ 4,800
Inflammatory Bowel Disease Agents	\$ 3,700	\$ 3,700

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	100%	-32%	5%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 260,056	\$ 46,241	\$ 224,192	\$ 270,434	\$ 46,241	\$ 24,979	54%	\$ (10,377)

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
CYSTIC FIBROSIS AGENTS	\$ 132,730	\$ (6,636)
INCRETIN MIMETIC AGENTS	\$ 24,213	\$ (3,296)
ANTIPSORIATICS	\$ 21,017	\$ (721)
INSULIN	\$ 13,352	\$ (2,993)
AMPHETAMINES	\$ 11,040	\$ 1,793
ANTI-OBESITY AGENTS	\$ 9,539	\$ 7,558
SYMPATHOMIMETICS	\$ 7,290	\$ (2,524)
DIABETIC SUPPLIES	\$ 6,231	\$ (5,594)
ESTROGENS	\$ 3,181	\$ 693
PROSTAGLANDINS - OPHTHALMIC	\$ 3,080	\$ 121

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	3%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 376,170,873	\$ 99,564,359	\$ -	\$ 99,564,359	\$ 99,564,359	\$ 345,029	0%	\$ 276,606,514

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 149,095,696	\$ 99,318,543
Blood Glucose Regulators	\$ 55,885,016	\$ 31,687,380
Anti-obesity Agents	\$ 42,068,678	\$ 30,691,694
Antineoplastics	\$ 36,137,666	\$ 35,296,121
Respiratory Tract/Pulmonary Agents	\$ 27,804,321	\$ 23,999,993
Blood Products and Modifiers	\$ 20,743,543	\$ 17,816,143
Dermatological Agents	\$ 12,219,256	\$ 10,957,347
Antivirals	\$ 12,120,155	\$ 11,682,728
Central Nervous System Agents	\$ 10,542,734	\$ 10,031,309
Gastrointestinal Agents	\$ 9,553,808	\$ 5,125,256

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 213,182	\$ -	\$ -	\$ -	\$ -	\$ -	0%	\$ 213,182

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
MIGRAINE PRODUCTS	\$ 83,351	\$ 83,351
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 52,434	\$ 52,434
CHEMICALS	\$ 19,647	\$ 19,647
ENDOCRINE AND METABOLIC AGENTS - MISC.	\$ 14,249	\$ 14,249
ANALGESICS - OPIOID	\$ 9,805	\$ 9,805
ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS	\$ 6,386	\$ 6,386
ANTIDIABETICS	\$ 4,323	\$ 4,323
ANTIVIRALS	\$ 3,755	\$ 3,755
OPHTHALMIC AGENTS	\$ 2,555	\$ 2,555
ANALGESICS - ANTI-INFLAMMATORY	\$ 1,832	\$ 1,832

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 175,000	\$ 19,000	\$ -	\$ 19,000	\$ -	\$ -	0%	\$ 156,000

Top 10 Categories by Spend - Descending Order		
Therapeutic Category	WAC	net WAC
Analgesics	\$ 50,000	\$ 45,000
Anesthetics	\$ 33,000	\$ 31,000
Blood Products/Modifiers/Volume Expanders	\$ 17,000	\$ 13,000
Antivirals	\$ 16,000	\$ 15,000
Respiratory Tract/Pulmonary Agents	\$ 15,000	\$ 13,000
Anticonvulsants	\$ 12,000	\$ 10,000
Anti-Addiction/Substance Abuse Treatment Agents	\$ 10,000	\$ 7,000
Blood Glucose Regulators	\$ 5,000	\$ 5,000
Ophthalmic Agents	\$ 3,000	\$ 3,000
MEDICAL DEVICES AND SUPPLIES	\$ 3,000	\$ 3,000

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	11%	4%	7%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 12,409,717	\$ 4,935,474	\$ 288,934	\$ 5,224,412	\$ 5,008,660	\$ 403,342	7%	\$ 7,185,304

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 5,216,967	\$ 2,911,505
Blood Glucose Regulators	\$ 2,552,764	\$ 1,149,789
Antineoplastics	\$ 928,921	\$ 866,070
Cardiovascular Agents	\$ 599,323	\$ 249,477
Blood Products and Modifiers	\$ 552,358	\$ 345,994
Antivirals	\$ 357,403	\$ 312,762
Anti-obesity Agents	\$ 320,678	\$ 215,057
Respiratory Tract/Pulmonary Agents	\$ 317,201	\$ 131,538
Antimigraine Agents	\$ 299,474	\$ 156,204
Dermatological Agents	\$ 291,322	\$ 160,674

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	100%	0%	37%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 792,831,000	\$ 4,471,000	\$ 699,284,000	\$ 703,755,000	\$ 4,486,000	\$ 22,000	0%	\$ 89,074,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 230,936,000	\$ 25,594,000
Blood Glucose Regulators	\$ 106,318,000	\$ 10,630,000
Antineoplastics	\$ 64,808,000	\$ 4,601,000
Respiratory Tract/Pulmonary Agents	\$ 50,525,000	\$ 3,676,000
Anti-obesity Agents	\$ 47,894,000	\$ 3,851,000
Antivirals	\$ 41,215,000	\$ (206,000)
Blood Products and Modifiers	\$ 37,227,000	\$ 5,141,000
Central Nervous System Agents	\$ 26,935,000	\$ 2,058,000
Dermatological Agents	\$ 20,166,000	\$ 6,812,000
Gastrointestinal Agents	\$ 15,459,000	\$ 1,837,000

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
n/a	0%*	0%*	0%*

* The value of rebates received is provided back to sponsors through discounted pricing.

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 1,000,601	\$ 75,127	\$ (15,770)	\$ 59,357	\$ 59,357	\$0*	0%*	\$ 941,244

* The value of rebates received is provided back to sponsors through discounted pricing.

Top 10 Categories by Spend - Descending Order		
Therapeutic Category	WAC	net WAC
Analgesics	\$ 227,843	\$ 204,295
Immunological Agents	\$ 95,832	\$ 92,723
Antimigraine Agents	\$ 88,098	\$ 76,636
Anticonvulsants	\$ 85,735	\$ 87,970
Respiratory Tract/Pulmonary Agents	\$ 73,572	\$ 73,133
Antivirals	\$ 60,801	\$ 57,620
Skeletal Muscle Relaxants	\$ 54,945	\$ 55,782
Antibacterials	\$ 53,388	\$ 53,750
Products Without a USP Category	\$ 50,083	\$ 49,493
Metabolic Bone Disease Agents	\$ 32,789	\$ 27,976

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 148,095,000	\$ 29,799,000	\$ -	\$ 29,799,000	\$ -	\$ -	0%	\$ 118,296,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 37,241,000	\$ 22,620,000
Blood Glucose Regulators	\$ 21,095,000	\$ 11,723,000
Antivirals	\$ 16,614,000	\$ 16,220,000
Antineoplastics	\$ 13,295,000	\$ 13,051,000
Respiratory Tract/ Pulmonary Agents	\$ 10,400,000	\$ 9,469,000
Products Without a USP Category	\$ 7,382,000	\$ 6,955,000
Blood Products and Modifiers	\$ 6,806,000	\$ 5,691,000
Central Nervous System Agents	\$ 5,663,000	\$ 5,444,000
Dermatological Agents	\$ 5,142,000	\$ 4,535,000
Cardiovascular Agents	\$ 3,555,000	\$ 3,212,000

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	100%	8%	33%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 84,676,000	\$ 24,108,000	\$ 2,251,000	\$ 26,359,000	\$ -	\$ -	0%	\$ 58,317,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
BLOOD GLUCOSE REGULATORS	\$ 16,280,000	\$ 8,243,000
MISCELLANEOUS THERAPEUTIC AGENTS	\$ 13,590,000	\$ 8,521,000
IMMUNOLOGICAL AGENTS	\$ 9,002,000	\$ 5,133,000
RESPIRATORY TRACT/PULMONARY AGENTS	\$ 6,228,000	\$ 4,885,000
CARDIOVASCULAR AGENTS	\$ 5,915,000	\$ 3,002,000
ANTIVIRALS	\$ 5,041,000	\$ 4,905,000
CENTRAL NERVOUS SYSTEM AGENTS	\$ 3,498,000	\$ 3,326,000
ANTINEOPLASTICS	\$ 3,480,000	\$ 3,389,000
BLOOD PRODUCTS AND MODIFIERS	\$ 3,359,000	\$ 2,103,000
ANTIMIGRAINE AGENTS	\$ 2,381,000	\$ 1,101,000

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	100%	1%	50%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 39,447,798	\$ -	\$ 821,826	\$ 821,826	\$ 50,289	\$ 50,289	100%	\$ 38,625,972

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS	\$ 4,949,697	\$ 4,894,060
ANTIDIABETICS	\$ 4,939,025	\$ 4,902,524
DERMATOLOGICALS	\$ 3,618,136	\$ 3,597,569
ANALGESICS - ANTI-INFLAMMATORY	\$ 3,444,014	\$ 3,431,381
CARDIOVASCULAR AGENTS - MISC.	\$ 2,241,149	\$ 2,239,915
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 1,820,710	\$ 1,785,230
MEDICAL DEVICES AND SUPPLIES	\$ 1,666,176	\$ 1,642,975
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	\$ 1,658,024	\$ 1,656,045
RESPIRATORY AGENTS - MISC.	\$ 1,633,414	\$ 1,633,219
ANTIPSYCHOTICS/ANTIMANIC AGENTS	\$ 1,548,083	\$ 1,523,862

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	100%	1%	50%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 12,499,037	\$ 2,987,531	\$ 156,643	\$ 3,144,174	\$ 3,007,330	\$ 19,800	1%	\$ 9,354,863

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ANTIDIABETICS	\$ 2,629,995	\$ 1,486,432
ANTIPSYCHOTICS/ANTIMANIC AGENTS	\$ 922,862	\$ 891,140
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 1,229,933	\$ 830,336
ANTICOAGULANTS	\$ 1,164,718	\$ 581,120
HEMATOLOGICAL AGENTS - MISC.	\$ 582,127	\$ 579,724
DERMATOLOGICALS	\$ 676,687	\$ 539,095
PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	\$ 575,149	\$ 510,557
CARDIOVASCULAR AGENTS - MISC.	\$ 480,041	\$ 450,140
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	\$ 419,018	\$ 417,766
MEDICAL DEVICES AND SUPPLIES	\$ 344,143	\$ 256,494

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	6%	0%	2%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 686,488,000	\$ 200,453,000	\$ 23,331,000	\$ 223,794,000	\$ 223,794,000	\$ 78,000	0%	\$ 462,691,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ANALGESICS - ANTI-INFLAMMATORY	\$ 154,745,000	\$ 87,642,000
DERMATOLOGICALS	\$ 135,420,000	\$ 90,945,000
ANTIDIABETICS	\$ 131,526,000	\$ 75,109,000
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	\$ 34,461,000	\$ 32,282,000
ANTIVIRALS	\$ 27,504,000	\$ 24,660,000
ASTHMA AND BRONCHODILATOR AGENTS	\$ 22,403,000	\$ 14,695,000
ANTICOAGULANTS	\$ 21,337,000	\$ 15,681,000
ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS	\$ 20,715,000	\$ 16,050,000
PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	\$ 17,609,000	\$ 14,955,000
MIGRAINE PRODUCTS	\$ 16,978,000	\$ 10,566,000

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	100%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 3,627,137	\$ 403,986	\$ 2,147,513	\$ 2,551,499	\$ 448,665	\$ (155,227)	-35%	\$ 1,075,638

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Antigout Agents	\$ 650,526	\$ (113,923)
Genetic or Enzyme or Protein Disorder: Replacement, Modifiers, Treatment	\$ 342,263	\$ (12,508)
Antidepressants	\$ 334,602	\$ 301,306
Cardiovascular Agents	\$ 304,915	\$ 272,836
Immunological Agents	\$ 255,095	\$ (31,424)
Blood Glucose Regulators	\$ 246,171	\$ 6,601
Antibacterials	\$ 174,110	\$ 45,943
Antineoplastics	\$ 124,370	\$ 23,254
Anticonvulsants	\$ 124,088	\$ 101,546
Respiratory Tract/ Pulmonary Agents	\$ 117,204	\$ 45,899

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	100%	0%	22%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 3,787,480	\$ 1,038,186	\$ 70,622	\$ 1,108,808	\$ 1,108,808	\$ 244,601	22%	\$ 2,678,672

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ANTIHYPERGLYCEMICS	\$ 675,477	\$ 373,667
ANTIINFLAM.TUMOR NECROSIS FACTOR INHIBITING AGENTS	\$ 671,392	\$ 335,921
IMMUNOSUPPRESSANTS	\$ 374,506	\$ 238,357
ANTINEOPLASTICS	\$ 235,052	\$ 232,005
PSYCHOTHERAPEUTIC DRUGS	\$ 201,263	\$ 189,585
ANTIARTHRITICS	\$ 183,878	\$ 120,886
ANTI-OBESITY DRUGS	\$ 181,990	\$ 125,589
ANTICOAGULANTS	\$ 142,013	\$ 106,250
SKIN PREPS	\$ 125,358	\$ 96,438
ANTIASTHMATICS	\$ 119,111	\$ 94,907

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	14%	5%	10%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 1,507,000	\$ 419,000	\$ 36,000	\$ 455,000	\$ -	\$ -	0%	\$ 1,052,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
BLOOD GLUCOSE REGULATORS	\$ 390,000	\$ 208,000
CARDIOVASCULAR AGENTS	\$ 207,000	\$ 125,000
RESPIRATORY TRACT/PULMONARY AGENTS	\$ 156,000	\$ 103,000
ANTIMIGRAINE AGENTS	\$ 142,000	\$ 111,000
BLOOD PRODUCTS AND MODIFIERS	\$ 132,000	\$ 73,000
MISCELLANEOUS THERAPEUTIC AGENTS	\$ 68,000	\$ 41,000
CENTRAL NERVOUS SYSTEM AGENTS	\$ 61,000	\$ 61,000
IMMUNOLOGICAL AGENTS	\$ 57,000	\$ 44,000
ANTIDEPRESSANTS	\$ 38,000	\$ 36,000
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS)	\$ 37,000	\$ 36,000

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 5,256,876	\$ 372,888	\$ -	\$ 372,888	\$ -	\$ -	0%	\$ 3,944,269

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 1,938,003	\$ 1,830,941
Antivirals	\$ 1,094,194	\$ 991,228
Blood Glucose Regulators	\$ 511,701	\$ 442,578
Central Nervous System Agents	\$ 209,877	\$ 202,512
Antipsychotics	\$ 183,719	\$ 166,280
Respiratory Tract/ Pulmonary Agents	\$ 170,683	\$ 160,704
Antimigraine Agents	\$ 117,122	\$ 108,381
Blood Products and Modifiers	\$ 114,559	\$ 101,477
Antidepressants	\$ 113,614	\$ 108,523
Hormonal Agents, Stimulant/ Replacement/ Modifying (Sex Hormones/ Modifiers)	\$ 102,523	\$ 100,245

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	23%	21%	22%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 5,369,000	\$ 1,458,000	\$ 113,000	\$ 1,571,000	\$ -	\$ -	0%	\$ 3,798,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
BLOOD GLUCOSE REGULATORS	\$ 1,515,000	\$ 760,000
CARDIOVASCULAR AGENTS	\$ 567,000	\$ 341,000
BLOOD PRODUCTS AND MODIFIERS	\$ 428,000	\$ 233,000
RESPIRATORY TRACT/PULMONARY AGENTS	\$ 399,000	\$ 294,000
IMMUNOLOGICAL AGENTS	\$ 296,000	\$ 256,000
CENTRAL NERVOUS SYSTEM AGENTS	\$ 269,000	\$ 261,000
ANTINEOPLASTICS	\$ 241,000	\$ 241,000
MISCELLANEOUS THERAPEUTIC AGENTS	\$ 175,000	\$ 103,000
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS)	\$ 174,000	\$ 167,000
ANTIVIRALS	\$ 162,000	\$ 160,000

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 25,027,935	\$ 2,798,659	\$ 314,490	\$ 3,113,149	\$ 2,798,659	\$ -	0%	\$ 21,914,786

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Antidiabetics	\$ 5,891,537	\$ 4,023,354
Dermatologicals	\$ 3,556,557	\$ 3,498,284
Analgesics - Anti-Inflammatory	\$ 2,340,284	\$ 2,284,922
Antineoplastics And Adjunctive Therapies	\$ 1,727,302	\$ 1,723,120
Adhd/Anti-Narcolepsy/Anti-Obesity/Anorexiant	\$ 1,505,713	\$ 1,467,654
Antiasthmatic And Bronchodilator Agents	\$ 1,234,733	\$ 1,072,079
Anticoagulants	\$ 879,170	\$ 691,859
Antivirals	\$ 718,744	\$ 710,091
Migraine Products	\$ 631,994	\$ 474,911
Medical Devices And Supplies	\$ 601,969	\$ 454,280

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 356,115	\$ 119,334	\$ 16,273	\$ 135,607	\$ -	\$ -	0%	\$ 220,507

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ANTIDIABETICS	\$ 127,931	\$ 65,073
PASSIVE IMMUNIZING AND TREATMENT AGENTS	\$ 54,574	\$ 51,059
ANALGESICS - ANTI-INFLAMMATORY	\$ 36,260	\$ 15,407
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 33,445	\$ 23,399
DERMATOLOGICALS	\$ 27,794	\$ 14,910
ANTICOAGULANTS	\$ 24,074	\$ 16,216
MEDICAL DEVICES AND SUPPLIES	\$ 21,436	\$ 14,989
MIGRAINE PRODUCTS	\$ 11,147	\$ 5,792
CARDIOVASCULAR AGENTS - MISC.	\$ 5,504	\$ 4,711
ANTIVIRALS	\$ 4,358	\$ 4,100

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	100%	100%	100%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 2,812,306	\$ 429,709	\$ -	\$ 429,709	\$ 429,709	\$ 429,709	100%	\$ 2,382,597

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ANALGESICS - OPIOID	\$ 791,957	\$ 625,698
DERMATOLOGICALS	\$ 254,701	\$ 239,748
ANTICONVULSANTS	\$ 237,880	\$ 230,291
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 190,579	\$ 139,241
ANTIDEPRESSANTS	\$ 185,172	\$ 183,589
PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	\$ 177,976	\$ 146,971
MIGRAINE PRODUCTS	\$ 146,197	\$ 101,132
MUSCULOSKELETAL THERAPY AGENTS	\$ 137,355	\$ 137,355
ANTICOAGULANTS	\$ 115,032	\$ 73,694
ANALGESICS - ANTI-INFLAMMATORY	\$ 103,872	\$ 103,872

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2024

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	38%	6%	15%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 153,066,000	\$ 23,115,000	\$ 3,408,000	\$ 26,523,000	\$ 26,402,000	\$ 3,519,000	13%	\$ 126,543,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	Net WAC
Products Without USP Category	\$ 56,697,000	\$ 43,801,000
Immunological Agents	\$ 52,910,000	\$ 43,187,000
Antineoplastics	\$ 26,987,000	\$ 24,744,000
Ophthalmic Agents	\$ 5,524,000	\$ 5,089,000
Contraceptives	\$ 4,445,000	\$ 4,137,000
Respiratory Tract/Pulmonary Agents	\$ 2,178,000	\$ 2,081,000
Dermatological Agents	\$ 1,195,000	\$ 1,091,000
Blood Glucose Regulators	\$ 1,063,000	\$ 763,000
Gastrointestinal Agents	\$ 498,000	\$ 314,000
Central Nervous System Agents	\$ 493,000	\$ 380,000